Online inquiry

IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9125MR)

This product GTTS-WQ9125MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MUC1 gene. The antibody can be applied in Gastric Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001018016.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4582
UniProt ID P15941
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9125MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14757MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SGN-35
GTTS-WQ11499MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MetMAb
GTTS-WQ15950MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ11434MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI-8897
GTTS-WQ11797MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MK-3475
GTTS-WQ1055MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-621
GTTS-WQ11505MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MetMAb
GTTS-WQ4539MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-936558
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW